(Sharecast News) - Avacta Group reported a reduced pre-tax loss of £28.98m from continuing operations in 2024 on Friday, down from £31.13m the year prior, as it accelerated its transformation into a pure-play oncology biotech.
Group revenue rose marginally to £24.42m, driven by a 14.7% increase in sales from the diagnostics...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE